{"id":15912,"date":"2019-12-18T11:11:49","date_gmt":"2019-12-18T11:11:49","guid":{"rendered":"https:\/\/dejalex.com\/it\/2019\/12\/no-us-jurisdiction-over-claim-by-russian-pharmaceutical-company-for-violation-of-us-antitrust-laws-by-hofmann-la-roche\/"},"modified":"2019-12-18T11:13:57","modified_gmt":"2019-12-18T11:13:57","slug":"no-us-jurisdiction-over-claim-by-russian-pharmaceutical-company-for-violation-of-us-antitrust-laws-by-hofmann-la-roche","status":"publish","type":"post","link":"https:\/\/www.dejalex.com\/it\/2019\/12\/no-us-jurisdiction-over-claim-by-russian-pharmaceutical-company-for-violation-of-us-antitrust-laws-by-hofmann-la-roche\/","title":{"rendered":"NO US JURISDICTION OVER CLAIM BY RUSSIAN PHARMACEUTICAL COMPANY FOR VIOLATION OF US ANTITRUST LAWS BY HOFMANN-LA ROCHE"},"content":{"rendered":"<p>F.Hoffmann-La Roche (HLR) is part of the Swiss based multinational healthcare giant Roche, which manufactures leading cancer treatment drugs Avastin, Rituxan and Herceptin. Patent protection for these substances in Russia has expired, and generic company BIOCAD was successful in launching biosimilars of HLR\u2019s originator medicines in the Russian market in years 2014-2016. Roughly at the same time, Roche sharply reduced the prices of its branded medicines imported in Russia, thus hindering BIOCAD\u2019s market entry&#8230;<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-2114 aligncenter\" src=\"https:\/\/dejalex.com\/it\/wp-content\/uploads\/2019\/12\/20191218_BIOCAD-vs-Hoffmann-La-Roche-in-US-court-on-antitrust-law.jpg\" alt=\"\" width=\"557\" height=\"789\" \/><\/p>\n<p style=\"text-align: center;\"><a href=\"https:\/\/dejalex.com\/it\/wp-content\/uploads\/2019\/12\/20191218_BIOCAD-vs-Hoffmann-La-Roche-in-US-court-on-antitrust-law.pdf\" target=\"_blank\" rel=\"noopener\"><i  class=\"x-icon x-icon-download\" data-x-icon-s=\"&#xf019;\" aria-hidden=\"true\"><\/i> Scarica l&#8217;articolo<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>[x_icon type=\"tag\"] Propriet\u00e0 Intellettuale, Farmaceutico e Life Sciences, Russia<\/p>\n","protected":false},"author":3,"featured_media":220,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[429,370,341,422,307,239,427],"tags":[],"class_list":["post-15912","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-alisa-pestryakova-it","category-farmaceutico-e-life-sciences","category-proprieta-intellettuale","category-pubblicazioni","category-roberto-jacchia-it","category-russia-it","category-russian-brief-it"],"_links":{"self":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts\/15912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/comments?post=15912"}],"version-history":[{"count":2,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts\/15912\/revisions"}],"predecessor-version":[{"id":15914,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/posts\/15912\/revisions\/15914"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/media\/220"}],"wp:attachment":[{"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/media?parent=15912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/categories?post=15912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.dejalex.com\/it\/wp-json\/wp\/v2\/tags?post=15912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}